HBW 002
Alternative Names: HBW-002Latest Information Update: 25 Jul 2022
At a glance
- Originator Chengdu Hyperway Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 25 Jul 2022 Discontinued for Autoimmune disorders in China (unspecified route) (Chengdu Hyperway Pharmaceuticals pipeline, July 2022)
- 01 Dec 2021 Early research in Autoimmune disorders in China (unspecified route) (Chengdu Hyperway Pharmaceuticals pipeline, December 2021)